RU2018125622A3 - - Google Patents

Download PDF

Info

Publication number
RU2018125622A3
RU2018125622A3 RU2018125622A RU2018125622A RU2018125622A3 RU 2018125622 A3 RU2018125622 A3 RU 2018125622A3 RU 2018125622 A RU2018125622 A RU 2018125622A RU 2018125622 A RU2018125622 A RU 2018125622A RU 2018125622 A3 RU2018125622 A3 RU 2018125622A3
Authority
RU
Russia
Application number
RU2018125622A
Other languages
Russian (ru)
Other versions
RU2018125622A (ru
RU2733382C2 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2018125622A publication Critical patent/RU2018125622A/ru
Publication of RU2018125622A3 publication Critical patent/RU2018125622A3/ru
Application granted granted Critical
Publication of RU2733382C2 publication Critical patent/RU2733382C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2018125622A 2015-12-31 2016-12-05 Способ применения карримицина против резистентности инфекции, спровоцированной микобактерией туберкулеза RU2733382C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201511030787.7 2015-12-31
CN201511030787.7A CN105497053B (zh) 2015-12-31 2015-12-31 可利霉素在抗结核分枝杆菌感染中的应用
PCT/CN2016/108502 WO2017114095A1 (zh) 2015-12-31 2016-12-05 可利霉素在抗结核分枝杆菌感染中的应用

Publications (3)

Publication Number Publication Date
RU2018125622A RU2018125622A (ru) 2020-01-31
RU2018125622A3 true RU2018125622A3 (es) 2020-03-26
RU2733382C2 RU2733382C2 (ru) 2020-10-01

Family

ID=55705614

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018125622A RU2733382C2 (ru) 2015-12-31 2016-12-05 Способ применения карримицина против резистентности инфекции, спровоцированной микобактерией туберкулеза

Country Status (20)

Country Link
US (1) US11000708B2 (es)
EP (1) EP3384915B1 (es)
JP (1) JP6770584B2 (es)
KR (1) KR20180098624A (es)
CN (1) CN105497053B (es)
AU (1) AU2016382584B2 (es)
BR (1) BR112018013327A2 (es)
CA (1) CA3010020A1 (es)
CL (1) CL2018001804A1 (es)
CO (1) CO2018007133A2 (es)
DK (1) DK3384915T3 (es)
ES (1) ES2785644T3 (es)
MY (1) MY191800A (es)
PE (1) PE20190210A1 (es)
PH (1) PH12018501394A1 (es)
PL (1) PL3384915T3 (es)
RU (1) RU2733382C2 (es)
UA (1) UA121159C2 (es)
WO (1) WO2017114095A1 (es)
ZA (1) ZA201804398B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105497053B (zh) 2015-12-31 2018-02-13 沈阳福洋医药科技有限公司 可利霉素在抗结核分枝杆菌感染中的应用
CN110545820B (zh) * 2017-04-06 2023-01-10 沈阳福洋医药科技有限公司 可利霉素及其药学上可接受的盐在制备治疗和/或预防肿瘤药物方面的应用
CN110384710B (zh) * 2018-04-17 2023-01-10 沈阳福洋医药科技有限公司 一种用于预防和/或治疗疼痛的药物、组合产品及其应用
CN110384802B (zh) * 2018-04-17 2021-09-17 沈阳福洋医药科技有限公司 一种用于预防和/或治疗发热的药物、组合产品及其应用
CN113577086B (zh) * 2020-04-30 2023-05-02 沈阳福洋医药科技有限公司 异戊酰螺旋霉素类化合物或其组合物在制备治疗免疫失调的药物中的应用
WO2021219112A1 (zh) * 2020-04-30 2021-11-04 沈阳福洋医药科技有限公司 异戊酰螺旋霉素类化合物或其组合物在制备治疗脓毒症疾病药物中的应用
WO2022119899A1 (en) * 2020-12-02 2022-06-09 Shionogi & Co., Ltd. A medicament for treating mycobacterial infection characterized by combining a cytochrome bc1 inhibitor with clarithromycin or azithromycin

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2126108B1 (es) * 1971-02-25 1974-08-02 Rhone Poulenc Sa
US7098219B2 (en) * 2000-08-01 2006-08-29 Wockhart Limited Inhibitors of cellular efflux pumps of microbes
CN1237976C (zh) * 2003-12-23 2006-01-25 沈阳同联集团有限公司 必特螺旋霉素及其在抗感染性疾病中的应用
US20080161249A1 (en) * 2004-11-17 2008-07-03 Smithkline Beecham Corporation Use of Novel Antibacterial Compounds
DE102005058345A1 (de) * 2005-12-06 2007-06-14 Kern, Andreas, Dr. med. Verwendung eines oral einzunehmenden Antibiotikums
WO2008122038A1 (en) * 2007-04-02 2008-10-09 President And Fellows Of Harvard College Regulating autophagy
PL3210990T3 (pl) * 2010-05-25 2020-10-05 Shenyang Fuyang Pharmaceutical Technology Co., Ltd. Lewoizowalerylospiramycyna III i jej preparaty, sposoby wytwarzania i zastosowania
CA2800019C (en) * 2010-05-25 2015-05-26 Shenyang Tonglian Group Co., Ltd. Levocarrimycin, pharmaceutical compositions, preparation methods and uses thereof
JP6116206B2 (ja) * 2012-11-26 2017-04-19 クリニプロ株式会社 吸入用パウダーの製造方法
CN103142520B (zh) * 2013-03-15 2015-04-01 沈阳同联集团有限公司 一种可利霉素片及其制备方法
CN105497053B (zh) 2015-12-31 2018-02-13 沈阳福洋医药科技有限公司 可利霉素在抗结核分枝杆菌感染中的应用

Also Published As

Publication number Publication date
ES2785644T3 (es) 2020-10-07
EP3384915B1 (en) 2020-02-19
ZA201804398B (en) 2019-09-25
BR112018013327A2 (pt) 2018-12-04
CL2018001804A1 (es) 2018-09-28
AU2016382584A1 (en) 2018-07-26
JP6770584B2 (ja) 2020-10-14
KR20180098624A (ko) 2018-09-04
DK3384915T3 (en) 2020-05-04
JP2019501220A (ja) 2019-01-17
CN105497053B (zh) 2018-02-13
MY191800A (en) 2022-07-15
RU2018125622A (ru) 2020-01-31
PE20190210A1 (es) 2019-02-07
AU2016382584B2 (en) 2022-01-06
PL3384915T3 (pl) 2020-09-07
WO2017114095A1 (zh) 2017-07-06
CN105497053A (zh) 2016-04-20
PH12018501394A1 (en) 2019-02-27
US20190001160A1 (en) 2019-01-03
CA3010020A1 (en) 2017-07-06
UA121159C2 (uk) 2020-04-10
EP3384915A4 (en) 2018-12-19
EP3384915A1 (en) 2018-10-10
US11000708B2 (en) 2021-05-11
RU2733382C2 (ru) 2020-10-01
CO2018007133A2 (es) 2018-07-19

Similar Documents

Publication Publication Date Title
RU2018125622A3 (es)
RU2018125487A3 (es)
BR112018003358A2 (es)
BE2015C047I2 (es)
BE2015C044I2 (es)
BR0010150B1 (es)
BR0006634B1 (es)
BR0002802B1 (es)
BR0009761B1 (es)
BR0002435B1 (es)
BR0002874B1 (es)
BR0002033B1 (es)
BR0001810B1 (es)
BR0001684B1 (es)
BR0001536B1 (es)
BR0000763F1 (es)
BR0000695B1 (es)
BR0000126B1 (es)
CN303127491S (es)
CN303109602S (es)
CN303082677S (es)
BR9915251B1 (es)
BR0009717B1 (es)
BR0103702B1 (es)
BR0008604B1 (es)